Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy (Q40963463)

25 September 2017

1 reference

title

Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy (English)

1 reference

25 September 2017

Haagen IA

1

1 reference

25 September 2017

publication date

1 November 1995

1 reference

25 September 2017

1 reference

25 September 2017

volume

19

1 reference

25 September 2017

issue

5-6

1 reference

25 September 2017

page(s)

381-393

1 reference

Drug sensitivity assays in leukaemia and lymphoma

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Recent advances in cellular immunology: implications for immunity to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Cytokine combinations in immunotherapy for solid tumors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Interleukin-2 in cancer treatment: disappointing or (still) promising? A review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Tumor necrosis factor (TNF).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Immunotherapy of cancer using interleukin 2: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Antibody production by hybridomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Use of anti-receptor antibodies to focus T-cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Bispecific F(ab′γ)3 antibody derivatives for redirecting unprimed cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

The use of hybrid hybridomas to target human cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Antigenic modulation - a major mechanism of antibody action

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Hybrid antibodies can target sites for attack by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

T-cell based cancer immunotherapy: direct or redirected tumor-cell recognition?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Targeting of anti-tumor responses with bispecific antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Triggering T cells by otherwise inert hybrid anti-CD3/antitumor antibodies requires encounter with the specific target cell

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Induction of cytotoxicity in human T cells coated with anti-glioma x anti-CD3 bispecific antibody against human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Preliminary trial of specific targeting therapy against malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Immunosuppression with monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Regulatory role of CD19 molecules in B-cell activation and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Inhibition of B cell proliferation with anti-CD19 monoclonal antibodies: anti-CD19 antibodies do not interfere with early signaling events triggered by anti-IgM or interleukin 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Immunobiologic differences between normal and leukemic human B-cell precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Inhibition, by vinca alkaloids and colchicine, of antigenic modulation induced by anti-CD19 monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Costimulation of T cells for tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Isotype-specific cross-linking of select human Fc gamma R isoforms triggers release of IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Functional characterization of a novel anti-B7 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Expression of LFA-1 in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Hierarchy of in vitro sensitivity and resistance of tumor cells to cytotoxic effector cells, cytokines, drugs and toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

How B and T cells talk to each other

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Transactivation by AP-1 is a molecular target of T cell clonal anergy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

IL2 treatment for cancer: from biology to gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Role of the CD28 receptor in T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Clinical implications of the polymorphic interaction of murine IgG2b and IgG1 with human Fc receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Comparative efficiencies of bispecific F(ab'gamma)2 and chimeric mouse/human IgG antibodies in recruiting cellular effectors for cytotoxicity via Fc gamma receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Characterisation of a humanised bispecific monoclonal antibody for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Univalent antibodies kill tumour cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

Acquisition of specific cytotoxic activity by human T4+ T lymphocytes in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509112195

10.3109/10428199509112195

21 January 2018

Identifiers

DOI

1 reference

25 September 2017

1 reference